WHO and Partners Will Organize Large International Study for Robust COVID-19 Data
In a daily press briefing on March 18, 2020, the World Health Organization (WHO) announced that, along with its partners, it will be organizing a large international study that will compare various untested treatments for COVID-19.
In a daily press briefing on March 18, 2020, the World Health Organization (WHO) announced that, along with its partners, it will be organizing a large international study that will compare various untested treatments for COVID-19.
The Solidarity Trial has been designed to generate sufficient data so that it will be possible to find the treatments that are most effective at treating COVID-19. Additionally, in the briefing, it was revealed that the procedures for the trial have been simplified so that hospitals, which are currently dealing with a large influx of work, can participate.
Countries that have already confirmed participation in the Solidarity Trial are Argentina, Bahrain, Canada, France, Iran, Norway, South Africa, Spain, Switzerland, and Thailand. Funding for the trial has reached US$43 million already, which has been received from over 173,000 individuals and organizations.
Source: WHO
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
